High Tide Inc. (HITI) has announced that its German subsidiary, Remexian Pharma GmbH, reached record distribution levels this quarter, showcasing continued growth in Europe's largest medical cannabis market.
For the second fiscal quarter ending April 30, 2026, Remexian sold 7.6 tonnes of medical cannabis in Germany. This is the highest volume they've ever recorded in a single quarter, reflecting a 21 percent increase from the previous quarter and a 49 percent jump compared to the same time last year.
CEO Raj Grover remarked that this achievement underscores the effectiveness of their distribution model, which leverages Remexian's local operations and High Tide's extensive procurement know-how gained from over $2.2 billion in cannabis sales in Canada.
Germany continues to be a vital growth area, having imported 201.1 tonnes of medical cannabis in 2025, more than double what they brought in the year before.
High Tide plans to build on this success by broadening its distribution strategy into more European markets, pending the necessary regulatory approvals.
The company also pointed out that the tonnage numbers are preliminary and haven't been audited. They expect to release complete financial results for the quarter, including revenue and earnings, in June 2026.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.